The Phase III, randomized, double-blind, placebo-controlled trial aims to evaluate the efficacy and safety of a single intervertebral local administration of AGA111 in patients with degenerative disc disease undergoing lumbar interbody fusion. Over 30 elite spine surgery centers are participating in this study, and the first subject was dosed successfully on 8th December 2023.
“In an aging society, nonunion after spinal fusion surgery has become a disturbing risk for patients undergo spinal fusion surgery. Based on the encouraging Phase I/II trial results, we believe that AGA111 has the potential to significantly accelerate bony fusion, reduce nonunion rate, and meaningfully improve patient outcomes. We are delighted to share this exciting news which is an important milestone for the AGA111 program. Angitia will continuously focus on clinical development of AGA111 with the aim of bringing this innovative therapy to help patients in need.” said Willard Dere, M.D., Chief Medical Officer of Angitia.
About Spinal Fusion
Spinal fusion is a widely used surgical treatment for spinal disorders. The incidence of nonunion after spinal fusion surgery has been reported as high as 56% in the lumbar spine [1]. A large case report shows that up to 23.6% of spinal revision surgery is related to nonunion [2]. Nonunion of the spine has significant adverse impact on postoperative function and clinical outcomes [3].
About Angitia Biopharmaceuticals
Founded in 2018, Angitia is a clinical-stage biotechnology company focused on the discovery and development of breakthrough therapeutics that address the key unmet medical needs in serious musculoskeletal disease. With the team’s experience and scientific expertise in novel drug development, Angitia is dedicated to bringing innovative therapies to help patients in need.
Learn more at www.angitiabio.com.
Reference
1. Lee C, Dorcil J, Radomisli TE. Nonunion of the spine: a review. Clin Orthop Relat Res. 2004;(419):71-75. doi:10.1097/00003086-200402000-00012
2. Raizman NM, O'Brien JR, Poehling-Monaghan KL, Yu WD. Pseudarthrosis of the spine. J Am Acad Orthop Surg. 2009;17(8):494-503. doi:10.5435/00124635-200908000-00003
3. Tsutsumimoto T, Shimogata M, Yoshimura Y, Misawa H. Union versus nonunion after posterolateral lumbar fusion: a comparison of long-term surgical outcomes in patients with degenerative lumbar spondylolisthesis. Eur Spine J. 2008;17(8):1107-1112. doi:10.1007/s00586-008-0695-9
Forward-Looking Statement
This press release is prepared by Angitia (the “Company", “We”) for informational purposes only. Forward-looking statements include all statements that are not historical facts and, in some cases, can be identified by terms such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “continue,” “could,” “potential,” “may,” “will,” “goal” or similar expressions and the negatives of those terms. However, not all forward-looking statements contain these identifying words.
These forward-looking statements are based on the current projects, expectations, assumptions, and understandings of the Company with respect to future events as of the date these statements are made. These statements are not a guarantee or warranty of future developments or otherwise.
These statements involve substantial known and unknown risks, uncertainties, and other factors that are beyond the Company’s control and are difficult to predict and may cause our actual results, timing of results, or achievements to be materially different from the information expressed or implied by these forward-looking statements. We anticipate that subsequent events and developments may cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law.
Except as expressly required by law, the Company and/or its officers, directors, employees, and agents shall not assume responsibility for the accuracy and completeness of the forward-looking statements in the information provided.